Results 251 to 260 of about 1,271,708 (300)

Inhibitors of HIV‐1 Reverse Transcriptase

2008
Publisher Summary With the identification of human immunodeficiency virus (HIV)‐1 as the infectious agent leading to acquired immune deficiency syndrome (AIDS), the viral reverse transcriptase (RT) has been a primary focus for drug discovery and development. Currently, two classes of RT inhibitors are used clinically. Nucleoside reverse transcriptase
Tatiana, Ilina, Michael A, Parniak
openaire   +2 more sources

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children

Clinical Drug Investigation, 2007
By the end of 2006, approximately 2.3 million children worldwide were living with HIV infection, representing about 15% of all HIV-infected individuals but only 5-7% of the total population of treated patients worldwide. Despite a general increase in the use of antiretroviral therapy (ART) in resource-limited settings, appropriate care and ART remain ...
GIAQUINTO, CARLO, RAMPON O, PENAZZATO M, FREGONESE F, DE ROSSI, ANITA, D'ELIA R.   +5 more
openaire   +3 more sources

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

AIDS, 2009
The use of nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor regimen for the treatment of antiretroviral-naive patients was less successful than classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen and associated with more resistance for protease inhibitors and NNRTIs. The selection for NNRTI resistance was
Cathia, Soulié, Lambert, Assoumou, Jade, Ghosn, Claudine, Duvivier, Gilles, Peytavin, Zaina, Ait-Arkoub, Jean-Michel, Molina, Dominique, Costagliola, Christine, Katlama, Vincent, Calvez, Anne-Geneviève, Marcelin   +10 more
openaire   +2 more sources

Quinolinehydrazones as inhibitors of retroviral reverse transcriptase.

Farmaco (Societa chimica italiana : 1989), 1992
The inhibitory activity of a series of 2- and 4-quinolinehydrazones on retroviral reverse transcriptase has been studied on enzymes from M-MuLV, RAV-2, and on a crude lysate of HIV-1, assuming the first two enzymes as potential models of the third. The highest activity is mainly found in lipophilic, water soluble 4-quinolinehydrazones.
C. Bartolucci, L. Cellai, DI FILIPPO, PATRIZIA, V. Brizzi, C. Pellerano, L. Savini, A. Benedetto, G. Elia   +7 more
openaire   +2 more sources

Coumarins as Inhibitors of HIV Reverse Transcriptase

Current HIV Research, 2006
Acquired immunodeficiency syndrome (AIDS), a degenerative disease of the immune and central nervous systems, is an enormous world-wide health threat. No cure has been found, and research is aimed at developing chemotherapy against the causative agent, human immunodeficiency virus (HIV).
openaire   +2 more sources

Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 1995
The majority of antiretroviral agents used in the treatment of HIV are targeted at the HIV reverse transcriptase (RT) enzyme. In a continuing effort to develop more effective antiviral regimens, drugs that target other specific enzymes in the virus replication cycle are under development. A promising new class of drugs is the protease inhibitors. These
openaire   +2 more sources

Use of nonnucleoside reverse-transcriptase inhibitors

American Journal of Health-System Pharmacy, 1998
C D, Holtzer, R L, Coleman
openaire   +2 more sources

Nucleoside reverse transcriptase inhibitors/nucleotide reverse transcriptase inhibitors

Reactions Weekly, 2019
openaire   +1 more source

[Reverse transcriptase inhibitors, protease inhibitors].

Nihon rinsho. Japanese journal of clinical medicine, 2012
These are six different classes of antiretroviral drugs that are nucleoside/nucleotide reverse transcriptase inhibitors(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 inhibitors and integrase inhibitors. NRTIs are thought as backbone of HAART(highly active antiretroviral therapy) and
openaire   +1 more source

Emerging reverse transcriptase inhibitors for HIV-1 infection

Expert Opinion on Emerging Drugs, 2018
Carl Fichtenbaum
exaly